Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|March 1, 2013
- Pharmaceutical Executive-03-01-2013
- Volume 0
- Issue 0
PE, March 2013 Cover Image
S
Advertisement
Cover
Articles in this issue
over 13 years ago
Less Selling, More Timeover 13 years ago
Test and Learn: Making Confident Decisions on the Commercial Sideover 13 years ago
China and the Emerging Markets Challengeover 13 years ago
Embedding Market Access in Today's Pharma Business Modelover 13 years ago
Who's Really in Charge of European Drug Registration?over 13 years ago
Brand of the Year: Januviaover 13 years ago
Early Engagement with Medical Laboratoriesover 13 years ago
Pharma in the News: Pharm Exec's Annual Press Auditover 13 years ago
Safeguarding the Value of Patent AssetsAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
2
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
3
Post-Exposure Prophylaxis Is the Missing Piece: Q&A with Florin Draica
4
Evidence With Purpose: Making Real-World Research Better, Not Just Faster
5